Principal Investigator: Ava Avalos, MD
Study Objectives
Primary Objectives
A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)/ Tatelo Study
Principal Investigator Initiated
Study Objectives:
A cross-sectional evaluation of antibody responses to SARS-COV-2 vaccines
Principal Investigator Initiated
Principal Investigator - Professor Mosepele Mosepele MD, MSc
Study Objectives
Primary Objectives:
- To evaluate SARS-CoV-2-specific qualitative antibody responses after the administration of full vaccination doses (either single or second doses) of vaccines in Botswana.
- To evaluate SARS-CoV-2-specific quantitative antibody responses after the administration of full doses of vaccines in Botswana.
Secondary Objectives:
A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting
Principal Investigator Initiated
Principal Investigator : Ponego Lloyd Ponatshego MD, MSc
Study Objectives:
Primary Objective
A Phase I, Randomized, Placebo-Controlled Study of the Safety, Antiviral & Immunomodulatory Activity of Broadly Neutralizing Antibodies 3BNC117-LS-J and 10-1074-LS-J in Combination in ART-treated Adults in sub-Saharan Africa Living with HIV during a Monit
Principal Investigator Initiated
Principal Investigator: Ayotunde E. Omoz-Oarhe (MD, MPH)
Study Objectives
Primary Objective:
A Randomized, Double-Blinded, Placebo-Controlled Study of the Combination of Two Long-Acting Broadley Neutralizing Antibodies at ART Initiation in Adults Living With HIV-1 in Sub-Saharan Africa (version 1.0 July 20,2023 for site 12701)
Principal Investigator Initiated
Principal Investigator: Ayotunde E. Omoz-Oarhe(MD,MPH)
Study Objectives:
Primary Objectives
Albuminuria Among Virally Suppressed HIV-infected Patients in Botswana: Longitudinal Changes and Association with Inflammation and ACEI/ARB Use in a Clinical Setting - Albuminuria Study
Principal Investigator Initiated
Principal Investigator - Professor Mosepele Mosepele, MD, MSc
Study Status: The study opened on January 22, 2020 and accrual completed on January 27, 2021. Participant follow up ongoing.
Study Objectives:
Aspirin, antenatal micronutrients, and azithromycin (AAA) trial for maximal reduction of preterm birth and related outcomes
Principal Investigator Initiated
Principal Investigator: Chelsea Morroni, MPH, MPhil, PhD, MBChB, DTM&H, DFSRH
Study Objectives:
Assessment of Proviral Reservoir: Sub study to determine the role of the immune system on the reservoir.
Principal Investigator Initiated
Principal Investigator
Assessment of Proviral Reservoir: Synergistic combination of reporter cell assay and viral diversity
Principal Investigator Initiated
Principal Investigators - Dr. Sikhulile Moyo, MSc, MPH, PhD | Dr. Catherine K. Koofhethile, PhD
Study Objectives: This study has two main goals:
Birth Outcomes Surveillance Study: Tsepamo Study
Principal Investigator Initiated
Principal Investigator - Professor Roger L. Shapiro, MD, MPH
Study Objectives
Primary Objectives
Botswana Safe Birth Study
Principal Investigator Initiated
Principal Investigator: Rebecca Luckett MD MPH
Study Objectives
Objective 1: Improve the quality of decision making around caesarean section
Cellular and humoral immune response in HIV-1-infected children receiving SARS-CoV2-specific mRNA vaccines in Botswana
Principal Investigator Initiated
Principal Investigator: Catherine Koofhethile, PhD and Mathias Lichterfeld, PhD
Study Objectives:
To assess cellular and humoral immune responses in HIV-1-infected children and teenagers receiving SARS-CoV2-specific mRNA vaccines in Botswana.
Characterization of Anthracycline induced Cardiotoxicity Using Cardiac Magnetic Resonance in Botswana: A Prospective Observational study (Pelo Study)
Principal Investigator Initiated
Principal Investigator - Dr. Scott Dryden-Peterson MD, MSc
Study Objectives
Aim 1: The study will compare the LVEF between patients with and without HIV who are being treated with anthracyclines. We hypothesize that the LVEF will be lower after anthracycline among individuals living with HIV.
Cognitive Testing of a survey instrument to assess sexual practices, behaviours, and health-related outcomes
Principal Investigator Initiated
Principal Investigator: Chelsea Morroni, MPH, MPhil, PhD, MBChB, DTM&H, DFSRH
Study Objectives:
Contraceptives and Dolutegravir-based ART (CODA) Study
Principal Investigator Initiated
Principal Investigator - Dr. Chelsea Morroni, MD, MPH, PhD
Name of the Study: The Contraceptives and Dolutegravir-based ART (CODA) Study
Study Status: Recruiting
Study Objectives:
Doris Duke Study: Adverse Cardiometabolic Impact of Antiretroviral Treatment Regimens Among Pregnant and Post-Partum Women and Their Infants
Principal Investigator Initiated
Principal Investigator: Rebecca Zash, MD
Study Objectives:
Primary objectives
Dual HIV/syphilis point-of-care testing to improve identification and treatment of syphilis among pregnant women in Gaborone, Botswana
Principal Investigator Initiated
Study Objectives: To determine the acceptability, feasibility, and costs of implementing point-of-care syphilis testing and treatment among pregnant women in Gaborone, Botswana.
Study Design: Cohort study
DYNAMICS OF HIV-1 IN RECENTLY DIAGNOSED INDIVIDUALS IN BOTSWANA IN THE ERA OF “TREAT ALL”
Principal Investigator Initiated
Principal Investigator: Natasha Onalenna Moraka
Study Objectives:
General Aim
This study aims to study the viral dynamics of recently diagnosed people living with HIV in the era of “Treat all” in Botswana.
Early Infant Treatment Study: A Clinical Trial of HIV Positive Infants in Botswana
Principal Investigator Initiated
Principal Investigator - Professor Roger L. Shapiro, MD, MPH
Study Objectives
The overall objective of the EIT study is to determine whether very early antiretroviral treatment (ART) initiation in HIV-infected infants limits the seeding of viral reservoirs and maintains immune responses, potentially allowing future periods off ART.
Specific Aims:
